Introduction
Skin soft tissue infections are inflammational diseases of skin and subcutaneous tissue caused by pathogens such as bacteria, fungi, and cover a wide range of diseases such as gills, gills, beehive inflammation and diarrhea, with a high incidence, with some impact on the life and health of patients. The timely and accurate selection of appropriate antibacterial drugs for treatment in primary health-care institutions is essential, and AchCin, because of its unique antibacterial spectrogen and pharmacological dynamics, is one of the most common drugs used to treat skin soft tissue infections, but to ensure their correct use, avoid abuse and unreasonable application.
II. Pharmacological effects of Archicin
Archicin is an antibiotic of the Great Ringed esters, which act mainly by inhibiting the synthesis of bacterial proteins through a combination of 50S of bacterial nuclei. It has a strong antibacterial activity for gland positive bacteria, such as yellow grapes and scavenger streptococcus, and has some effect on some gland vaginal bacteria, such as haemophilus influenzae, cartamola, etc., as well as on atypical pathogens, such as chlamydia, spastas. This broad spectrum antibacterial properties allow for the coverage of a wide range of possible pathogens in the treatment of skin soft tissue infections.
III. Adaptation
At the primary level, AchCin is used in cases of light and moderate skin soft tissue infections caused by sensitive bacteria, such as swollen swollen, scabies, Danoxin, etc., and skin soft tissue inflammation due to chlamydia, chlamydia and spa infections. Archicillin is also an alternative drug option for patients who are allergic to penicillin. However, in cases of severe skin soft tissue infections, especially when combined with all-body symptoms such as high fever, sepsis or suspected drug-resistant infections, the simple use of Achicillin may not be effective in controlling the condition, and joint medication or referral to a higher hospital for further treatment is considered.
IV. Usage
Archicillin has a variety of formulation types, including tablets, capsules, granules, etc., and is used at the grass-roots level with a reasonable choice of the formulation type and determination of the dose, depending on the age, condition and weight of the patient. For adults, the first dose of treatment for skin soft tissue infections is, in general, 500 mg (mg) for the first time, or 250 mg (mg) daily at 2-5 days, or a programme of 500 mg (mg) daily for three days, with a total treatment of 3-5 days. In the case of children, the weight of 10 mg/kg at day 1 (up to 500 mg per day) and the weight of 5 mg/kg at day 2 – 5 (up to 250 mg per day) at day 2 – 5 (up to day) are adjusted appropriately for skin soft tissue infections, usually 10 mg/kg at day 1, followed by 5 mg/kg for 2 – 4 days depending on the condition of the patient.
V. Adverse effects monitoring
In the treatment of Achicillin, the possible adverse reactions of the patient require close attention. Common adverse effects include gastrointestinal responses, such as nausea, vomiting, abdominal pain, diarrhoea, etc., which are relatively light and most patients can endure. A small number of patients may have allergies, such as rashes, itchings, etc., which should be discontinued as soon as they appear and treated for allergies in accordance with the level of allergy. In addition, hepatic function abnormalities may occur in the form of increased remission enzymes, so that hepatic function can be considered for monitoring before and after use of the drug, especially for patients with long-term or large doses of Achicillin, as well as patients with their own underlying liver disease. If hepatic function is clearly abnormal, hepatic care should be taken in a timely manner.
VI. NOTES
1. Drug interaction: Basic medical personnel should be aware of the interaction of accein with other drugs. For example, its co-use with tea alkali drugs may increase haematological concentrations of tea alkalis, leading to an increased risk of tea alkali poisoning, which, if used at the same time, should be closely monitored and dosage adjusted as appropriate; and, when used with drugs such as geoincin, it may increase haemopharmacin concentrations, causing adverse effects such as cardiac disorders, as well as careful use and monitoring of haemophatoxin concentrations.
2. Drugs for specific population groups: for pregnant and lactating women, the use of acceacin should be weighed against the pros and cons and should be used with caution only if the benefit is clearly greater than the risk; for older persons, because of the possible reduction in their liver and kidney function, the use of drugs needs to be adjusted to the kidney function, as appropriate, and the monitoring of adverse effects should be strengthened; for children, the drug should be given strictly in accordance with the child ‘ s dose, so as to avoid excessive use leading to serious adverse effects.
3. Drug resistance: With the widespread use of Archicin, bacteria are increasing their resistance. Primary health care institutions should, to the extent possible, conduct bacterial training and drug-sensitization tests before using acceleroxin, make a rational choice of antibacterial drugs based on the results of the drug-sensitization process, and avoid blind empirical drug use leading to the creation and spread of drug-resistant bacteria. In the case of patients with poor Achicillin treatment, treatment should be adjusted in a timely manner to replace other sensitive antibacterial drugs.
Conclusion
Archicillin is an effective antibacterial option in treatment of skin soft tissue infections in primary medical institutions. However, in order to achieve its proper use, medical personnel at the grass-roots level must have full knowledge of its pharmacological role, adaptability, usage, adverse response monitoring and care. In clinical practice, individualized treatment should be carried out in strict compliance with the principle of reasonable use of medicines, taking into account the specific circumstances of the patient, and drug education and follow-up should be strengthened to ensure the safe and effective application of Achicillin in the treatment of skin soft tissue infections, to improve the level of treatment of antibacterial drugs in primary health-care institutions and to promote the early rehabilitation of patients.
